Document is current
Any future updates will be listed below
-
Authors
Luijten, Ineke
Weng, Xiong
Kibildyte, Ula
Buchan, Jana
Onishi, Ami
Mann, Jake
McKay, Eleanor
Savage, David
Semple, Robert K.
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (2019-06422)
Wellcome Trust (216329, 219417, 210752)
National Institute for Health and Care Research (Cambridge Biomedical Research Centre)
Medical Research Council (MC_UU_00014/5)
British Heart Foundation (RE/18/5/34216)
- License Information
-
More Information
Article History
Received: 8 May 2025
Accepted: 24 June 2025
First Online: 4 August 2025
Declarations
:
: Dermal fibroblasts were derived from skin biopsies from healthy volunteers and three people with biallelic MFN2 mutations as previously described (Rocha ). Informed consent was obtained and confirmed in writing as part of studies approved by the UK National Research Ethics Committee (studies 18/EE/0068 and 12/EE/0405). All animal experiments were performed under UK Home Office Project License P87539BCC, approved by the University of Edinburgh Animal Welfare and Ethical Review Board, and conducted in line with ARRIVE guidelines.
: Not applicable.
: Really none are truly competing, but for full disclosure: RKS has received consulting fees from Novartis, Astra Zeneca, and Alnylam, and speaking fees from Novo Nordisk, Eli Lilly, Amryt/Chiesi, and Medscape.
